Brand Intelligence Graph
Company Overview
About Isomorphic Labs
Isomorphic Labs is an Alphabet company spun out of Google DeepMind to apply AI to the full drug discovery pipeline, from target identification through molecular design and clinical candidate selection. Founded in 2021 under CEO Demis Hassabis's vision of using AI to accelerate medicine, Isomorphic operates with the scientific resources and computational infrastructure of DeepMind while functioning as a standalone drug discovery organization. The company's founding mission is to use AI not merely as a tool to assist drug hunters, but as the primary engine of drug design — replacing the slow, expensive, and largely empirical process of traditional medicinal chemistry with AI-directed molecular engineering.
Business Model & Competitive Advantage
Isomorphic's core platform is the Drug Design Engine, a proprietary AI system built on top of AlphaFold architecture. The Drug Design Engine has achieved landmark performance results, reportedly doubling the accuracy of AlphaFold3 at predicting how small molecules bind to their protein targets — the fundamental problem in structure-based drug design. This capability enables Isomorphic to computationally design molecules predicted to bind their targets with far greater precision than conventional methods, potentially eliminating many of the expensive iterative cycles that make drug development so slow. The company has also established major pharma partnerships with Eli Lilly and Novartis to co-develop drug candidates across multiple therapeutic areas.
Competitive Landscape 2025–2026
Isomorphic raised $600M from Thrive Capital in 2024–2025, bringing substantial private capital alongside its Alphabet backing to accelerate pipeline development. As of 2026, the company is preparing for its first clinical trials — a critical milestone that will test whether its computational drug design predictions translate into human efficacy. With AlphaFold-derived technology at its core, partnerships with two of the world's largest pharmaceutical companies, and over half a billion in funding, Isomorphic Labs represents the most credentialed and well-resourced pure-play AI drug discovery company in existence.
Recent Activity
View all →Foreign Filing filed 2026-05-22
Foreign Filing filed 2026-05-14
Foreign Filing filed 2026-05-14
Foreign Filing filed 2026-05-14
Foreign Filing filed 2026-04-28
Annual Report (foreign) filed 2026-04-27
Foreign Filing filed 2026-04-01
Key Differentiators
Emerging Innovator
Isomorphic Labs is an emerging player bringing innovative solutions to the Healthcare & Life Sciences market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Compare Isomorphic Labs with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Isomorphic Labs? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Isomorphic Labs Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Isomorphic Labs vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →